OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Issue Information	383
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	236
Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients	157
In this Issue	112
	95
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective	87
The Broader Context of Liquid Biopsy in Absorption, Distribution, Metabolism, and Elimination	74
FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception	74
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	72
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	71
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	66
Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement	65
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence	64
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination	63
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs	62
Pharmacogenomic Prescribing Guidelines: Are They Always Useful?	61
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	60
The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities	59
Promoting Clinical Trial Diversity: A Highlight of Select US FDA Initiatives	56
Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria	55
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	54
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	53
Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies	52
Repeated Intake of Grapefruit Juice Inhibits CYP2B6 , CYP2C9 , CYP2C19	51
Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov	50

Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes	48
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience	48
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling	45
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study	44
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	43
Factors Influencing Medication Adherence in Heart Failure Patients—A Survey Among Cardiac Healthcare Providers	41
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization	40
ICH S7B In Vitro Assays Do Not Address Mechanisms of QT_C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT_C Studies	40
Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate	39
Why Pediatric CAR ‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe	38
	38
Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities	38
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers	37
Frequency of Key Pharmacogenes CYP2C9 , CYP2C19 , CYP2D6	37